Burkhard F. Leeb
Hollabrunn, Austria
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 39 publications
Incidence of Major Adverse Cardiovascular Events in Patients With Rheumatoid Arthritis Treated With JAK Inhibitors Compared With Biologic Disease-Modifying Antirheumatic Drugs: Data From an International Collaboration of Registries.
Journal: Arthritis & rheumatology (Hoboken, N.J.)
Published: November 07, 2024
Prediction of ineffectiveness of biological drugs using machine learning and explainable AI methods: data from the Austrian Biological Registry BioReg.
Journal: Arthritis research & therapy
Published: October 20, 2023
Evaluation of discontinuation for adverse events of JAK inhibitors and bDMARDs in an international collaboration of rheumatoid arthritis registers (the 'JAK-pot' study).
Journal: Annals of the rheumatic diseases
Published: July 06, 2023
After JAK inhibitor failure: to cycle or to switch, that is the question - data from the JAK-pot collaboration of registries.
Journal: Annals of the rheumatic diseases
Published: September 13, 2022
Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the 'JAK-pot' collaboration.
Journal: Annals of the rheumatic diseases
Published: April 01, 2022
What could a new disease activity score for polymyalgia rheumatica do better?
Journal: Nature reviews. Rheumatology
Published: December 01, 2020
Education in Times of the Pandemic, Change of Paradigms?
Journal: Rheuma plus
Published: September 28, 2020
Last Updated: 09/26/2026